Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells

Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression

(2020) Changlin Li et al.   CELLULAR ONCOLOGY

Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer

(2019) Changlin Li et al.   PROSTATE

Natural compound inducers of immunogenic cell death

(2019) Marc Diederich   ARCHIVES OF PHARMACAL RESEARCH

Immunogenic cell death in cancer therapy: Present and emerging inducers

(2019) Jingyi Zhou et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

eIF2α phosphorylation is pathognomonic for immunogenic cell death

(2018) Lucillia Bezu et al.   CELL DEATH AND DIFFERENTIATION

Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer

(2018) Gi-Hoon Nam et al.   Nature Communications

PKR and GCN2 stress kinases promote an ER stress-independent eIF2α phosphorylation responsible for calreticulin exposure in melanoma cells

(2018) Paola Giglio et al.   OncoImmunology

eIF2α phosphorylation: A hallmark of immunogenic cell death

(2018) Lucillia Bezu et al.   OncoImmunology

Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer

(2018) Xiaohong Xia et al.   Oncogenesis

Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases

(2018) Jianzhong Qin et al.   JOURNAL OF SURGICAL RESEARCH

A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study

(2017) Rahul Aggarwal et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Proteasome function shapes innate and adaptive immune responses

(2016) Ilona Elisabeth Kammerl et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death

(2016) Chiara Pozzi et al.   NATURE MEDICINE

The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells

(2016) T Colangelo et al.   Cell Death & Disease

Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis

(2016) Changlin Li et al.   Oncotarget

Immunogenic cell death

(2015) Abhishek D. Garg et al.   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

The 26S proteasome is a multifaceted target for anti-cancer therapies

(2015) Tatyana A. Grigoreva et al.   Oncotarget

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells

(2013) Jee-Eun Kim et al.   PHARMACOLOGICAL RESEARCH

MG132, a proteasome inhibitor, induces apoptosis in tumor cells

(2012) Na GUO et al.   Asia-Pacific Journal of Clinical Oncology

The role of the proteasome in the generation of MHC class I ligands and immune responses

(2011) E. J. A. M. Sijts et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

(2011) F. Saad et al.   CLINICAL CANCER RESEARCH

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

(2011) M. Michaud et al.   SCIENCE

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET